Harrow Health (NASDAQ:HROW) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Harrow Health (NASDAQ:HROW) posted its quarterly earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03), Fidelity Earnings reports. Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The business had revenue of $13.52 million during the quarter, compared to analysts’ expectations of $12.55 million.

NASDAQ HROW traded down $1.64 during mid-day trading on Thursday, hitting $4.76. The company’s stock had a trading volume of 78,090 shares, compared to its average volume of 253,168. The stock has a market cap of $157.36 million, a price-to-earnings ratio of 7.94 and a beta of 0.06. The company has a fifty day moving average price of $7.66. Harrow Health has a 52-week low of $2.22 and a 52-week high of $8.99. The company has a quick ratio of 3.22, a current ratio of 3.43 and a debt-to-equity ratio of 0.47.

In other news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $5.78, for a total transaction of $57,800.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert J. Kammer sold 6,500 shares of Harrow Health stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $6.89, for a total transaction of $44,785.00. The disclosure for this sale can be found here. Insiders have sold 23,000 shares of company stock worth $154,000 in the last quarter. Insiders own 12.43% of the company’s stock.

HROW has been the topic of several research reports. TheStreet upgraded shares of Harrow Health from a “d-” rating to a “c” rating in a report on Wednesday, May 1st. ValuEngine lowered shares of Harrow Health from a “hold” rating to a “sell” rating in a report on Monday. Finally, Zacks Investment Research lowered shares of Harrow Health from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Further Reading: What is Elliott Wave theory?

Earnings History for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.